Swiss Construction Stock News

In May 2026, Roche Holding and its Genentech unit presented new clinical data at the ASCO Annual Meeting, showcasing nine approved and investigational oncology medicines, with a particular emphasis on giredestrant in estrogen receptor-positive breast cancer across multiple disease stages. These data, including results from large Phase III trials such as lidERA and persevERA, underline Roche’s push to expand its breast cancer portfolio with targeted therapies that could reshape treatment...

Novartis (SWX:NOVN) plans to present extensive new data on late-stage cancer and immune disease therapies, including Pluvicto, Kisqali, Scemblix and ianalumab, at the 2026 ASCO and EHA congresses. The company is progressing treatments for rare conditions such as Charcot–Marie–Tooth disease alongside its broader oncology and hematology pipeline. Novartis is also participating in a major AI industry summit, highlighting its focus on digital tools across research and development. For investors...

Ypsomed Holding (SWX:YPSN) has put up a punchy set of FY 2026 numbers, with first half revenue at CHF 362.7 million and basic EPS of CHF 10.19, alongside trailing 12 month revenue of CHF 731.0 million and EPS of CHF 16.31 after a year in which earnings grew 153.6%. Over the past reported periods, the company has seen revenue move from CHF 324.0 million in H1 FY 2025 to CHF 424.9 million in H2 FY 2025 and then to CHF 362.7 million in H1 FY 2026, while EPS shifted from CHF 2.39 to CHF 4.02 and...

Recent share performance and business scale Nestlé (SWX:NESN) has drawn fresh investor attention after a recent stretch of mixed returns, with the stock up over the past month but down over the past 3 years and past 5 years. The company closed at CHF 78.80, with a return of about 0.2% over the past day, 2.5% over the past week and 4.6% over the past month, while the share price declined about 2.6% over the past 3 months. Over longer periods, Nestlé’s total return is up about 3.1% year to date...

Swisscom stock snapshot and recent performance context Swisscom (SWX:SCMN) has been drawing attention after recent price moves, with the stock up about 17.4% year to date and showing a total return of roughly 63.4% over five years. Over shorter periods, Swisscom’s share price has risen around 3.3% in the past month, while the past 3 months show a decline of about 3.3%, and the 1-day move reflects a fall of roughly 0.9%. See our latest analysis for Swisscom. At a share price of CHF680.0,...

Sika (SWX:SIKA) has opened its largest U.S. mortar production facility in Bridgeton, New Jersey. The highly automated plant is designed to serve demand in key northeastern metropolitan areas. The facility expands Sika's mortar manufacturing footprint in the northeastern U.S. construction market. Sika, listed as SWX:SIKA, supplies construction chemicals used across infrastructure, commercial buildings, and refurbishment projects. Mortar products are central to those applications, so...

In recent weeks, ams-OSRAM completed a major debt refinancing, upsizing a €1 billion senior unsecured notes issue due 2032 and extending its €600 million revolving credit facility, while also inviting shareholders to a June 10, 2026 AGM that will vote on amendments to its Articles of Association and board mandates. An additional catalyst came from a J.P. Morgan upgrade that highlighted AI photonics and smart glasses as key long-term technology opportunities for ams-OSRAM. Against this...

Montana Aerospace (SWX:AERO) moved into focus after reporting first quarter 2026 results, with sales of €249.34 million and net income of €10.34 million, compared with €240.48 million and €5.27 million a year earlier. See our latest analysis for Montana Aerospace. At a share price of CHF22.55, Montana Aerospace has seen its short term share price weaken, with the 30 day share price return down 11.39% and the 90 day share price return down 33.68%. However, the 3 year total shareholder return...

As European markets grapple with geopolitical tensions and inflationary pressures, the pan-European STOXX Europe 600 Index recently saw a decline of 0.85%, reflecting broader economic concerns. Despite these challenges, robust earnings growth in certain sectors highlights opportunities for investors seeking stable income through dividend stocks. In such an environment, a good dividend stock is characterized by consistent payout history and strong fundamentals that can withstand market...

Recent share performance and business scale Partners Group Holding (SWX:PGHN) has recently shown mixed share performance, with the stock up 1.1% over the past day and 2.9% over the past week, while down over the past month and past 3 months. At a last close of CHF 909.60 and a market value of about CHF 23.5b, the company is among the larger listed alternative asset managers. It is backed by CHF 2,554.8m in revenue and CHF 1,260.7m in net income. See our latest analysis for Partners Group...

Lonza Group (SWX:LONN) has drawn fresh attention after shareholders approved a CHF 5.00 per share dividend, a 25% year-on-year increase, alongside board and remuneration committee changes at the 8 May 2026 Annual General Meeting. See our latest analysis for Lonza Group. Alongside the higher dividend and refreshed board, Lonza Group’s 1-day share price return of 0.92% and 7-day share price return of 3.86% come against a year-to-date share price return that is down 8.05%, and a 1-year total...

Züblin Immobilien Holding AG's ( VTX:ZUBN ) recent weak earnings report didn't cause a big stock movement. However, we...

Despite posting healthy earnings, Adecco Group AG's ( VTX:ADEN ) stock has been quite weak. Our analysis suggests that...

ABB (SWX:ABBN) has put fresh attention on its stock after unveiling an IE6 hyper efficiency motor for hazardous areas and outlining a $200 million program to expand medium voltage manufacturing across Europe. See our latest analysis for ABB. The recent IE6 motor launch and the $200 million medium voltage expansion have landed against a strong backdrop, with ABB’s share price at CHF81.34 and a 30 day share price return of 9.53%, while the 1 year total shareholder return of 73.45% and 5 year...

Sonova Holding (SWX:SOON) has just reported first half FY 2026 revenue of CHF1.8 billion and basic EPS of CHF3.16, alongside trailing twelve month revenue of CHF3.6 billion and EPS of CHF9.02 that sit against a mixed track record of earnings and margin trends. The company has seen first half revenue move from CHF1.8 billion in FY 2024 to CHF1.8 billion in FY 2025 and CHF1.8 billion in FY 2026, while basic EPS over those same first half periods shifted from CHF5.97 to CHF3.50 and then CHF3.16...

Roche Group (SWX:ROP) and Genentech plan to present new clinical data across nine cancer medicines at the 2026 ASCO Annual Meeting. The program includes breast cancer results that may be important for clinical practice, with a focus on giredestrant, a selective estrogen receptor degrader. Data span both investigational and approved therapies, including antibody drug conjugates, bispecific antibodies, and treatments for several cancer types. The breadth of readouts could influence treatment...

Barry Callebaut (SWX:BARN) has put product development in the spotlight at the 2026 Sweets & Snacks Expo by reshaping its compound range into a new Cacao Coatings & Inclusions category and launching Cacao Max and cocoa free ChoViva. See our latest analysis for Barry Callebaut. Investors have reacted positively to Barry Callebaut’s recent product announcements, with the share price delivering a 1 month share price return of 12.81% even though the 3 year total shareholder return is down 31.70%,...

Amrize AG ( VTX:AMRZ ) shareholders (or potential shareholders) will be happy to see that the CEO & Chairman, Jan...

Today is shaping up negative for Landis+Gyr Group AG ( VTX:LAND ) shareholders, with the analysts delivering a...

Sonova Holding AG has released its full-year results for the period ended March 31, 2026, reporting sales of CHF 3,605.9 million, net income of CHF 430.6 million, and announcing an annual dividend of CHF 4.70 per share payable on June 23, 2026. Despite lower reported net income year-on-year, the company achieved 5.9% sales growth and a 17.3% increase in normalized EBITA in local currencies, primarily driven by its Hearing Instruments segment and supported by business reshaping and the...

As European markets navigate the challenges of geopolitical tensions and inflationary pressures, investors continue to seek stability and growth through dividend stocks. In such a climate, selecting stocks with robust earnings growth and consistent dividend payouts can be an effective strategy for those looking to generate income while potentially mitigating volatility.

Novartis (SWX:NOVN) is back in focus after new clinical data showed its radioligand therapy Pluvicto, when added to standard treatment, cut the risk of PSA progression by 58% in a specific prostate cancer setting. See our latest analysis for Novartis. Alongside the Pluvicto data and a series of US manufacturing and research expansions, Novartis has seen firm investor interest, with the share price at CHF117.2 and an 8.02% year to date share price return, while the 1 year total shareholder...

Investors may be asking whether Swisscom at CHF676.0 is offering fair value right now, or if the recent momentum has already priced in the opportunity. The stock has returned 1.0% over the past week, 3.9% over the past month, 16.8% year to date, and 27.2% over the last year, which naturally raises questions about how much of its potential is already reflected in the price. Recent attention on Swisscom has focused on its role as a major Swiss telecom operator and how investors view its...

In early May 2026, Novartis broke ground on a new 46,000 sq. ft radioligand therapy manufacturing facility in Denton, Texas, part of its US$23.00 billion US manufacturing and research expansion and its fifth radioligand therapy site nationwide. This build-out of a coast-to-coast radioligand therapy network highlights how Novartis is tying manufacturing proximity and reliability directly to complex cancer treatment delivery for US patients. We will now explore how this expanded US radioligand...